Considerations for Home-Based Treatment of Fabry Disease in Poland during the Covid-19 Pandemic and Beyond
Bibliographic Data
Current therapy for Anderson-Fabry disease in Poland includes hospital or clinic-based intravenous enzyme replacement therapy with recombinant agalsidase alpha or beta, or oral pharmacological chaperone therapy with migalastat. Some countries around the world offer such treatment to patients in the comfort of their own homes. The 2020-2021 COVID-19 pandemic has pushed global healthcare providers to evolve their services so as to minimize the risk of COVID-19 exposure to both patients and providers; this has led to advances in telemedicine services and the increasing availability of at-home treatment for various procedures including parenteral drug administration. A total of 80% of surveyed Anderson-Fabry disease patients in Poland would prefer home-based treatment, which would be a safe and convenient alternative to clinic-based treatment if patient selection is based on our proposed algorithm. Our recommendations for home-based treatments appear feasible for the long term care of Anderson-Fabry disease patients during the COVID-19 pandemic and beyond. This may also serve as a basis for home-based treatment programs in other rare and ultra-rare genetic diseases
Bioinformatics · Coronavirus disease 2019 (COVID-19 · Disease · Enzyme replacement therapy · Fabry disease · Health care · Infectious disease (medical specialty · Intensive care medicine · Medical emergency · Orphan drug · Pandemic · Pharmacotherapy · Telemedicine · Carbohydrate Chemistry and Synthesis · Lysosomal Storage Disorders Research · Medicine · Studies on Chitinases and Chitosanases · Internal Medicine
| Highly cited | No |
|---|